期刊文献+

三阴性乳腺癌分子靶向治疗的研究进展 被引量:2

Research Progress of Molecular Targeted Therapy for TNBC
下载PDF
导出
摘要 近年来,随着内分泌治疗、化疗、靶向治疗和放疗研究的深入,有效改善了乳腺癌预后。三阴性乳腺癌作为一种特殊型乳腺癌,其分子生物学特性以及病例均比较独特,目前分子靶向治疗被广泛应用于该病的治疗中,该研究笔者就三阴性乳腺癌分子靶向治疗的研究进展进行研究和分析,望可为临床治疗方案的明确提供参考依据,以此进一步提高治疗效果。 In recent years, with the depth of endocrine therapy, chemotherapy, targeted therapy and radiotherapy research, to effectively improve the prognosis of breast cancer. Three negative breast cancer as a special type of breast cancer, the molecular biological characteristics and cases are relatively unique, at present, molecular targeted therapy has been widely used in the treatment of the disease, the author carried on research and analysis to the research progress of the three negative molecular targeted therapy, expected that can provided reference for the definition of clinical treatment , on this account to improve further the effects of treatment.
作者 马燕飞 浦涧
出处 《中外医疗》 2015年第11期192-193,共2页 China & Foreign Medical Treatment
关键词 分子靶向 治疗 三阴性乳腺癌 Molecular targeting Treatment Three negative breast cancer
  • 相关文献

参考文献20

二级参考文献334

  • 1田富国,罗飞,赵浩亮.Aurora激酶A在三阴性乳腺癌中的表达及与临床病理特征的相关性[J].中国药物与临床,2011,11(S1):5-7. 被引量:2
  • 2Burstein HJ,Elias AD,Rugo HS,et al.Phase Ⅱ study of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor,in patients with metastatic breast cancer previously treated with an anthracycline and a taxane[J].J Clin Oncol,2008,26:1810-1816.
  • 3Baselga J,Roche H,Costa F,et al.SOLTI-0701:A Multinational Double-Blind,Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC)[J].Cancer Research,2009,69:497S-497S.
  • 4Gradishar WJ,Kaklamani V,Sahoo TP,et al.A Double-Blind,Randomized,Placebo-Controlled,Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer[J].Cancer Research,2009,69:496S-496S.
  • 5Burris HA,Ⅲ,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23:5305-5313.
  • 6Burstein HJ,Storniolo AM,Franco S,et al.A phase Ⅱ study of lapatinib monotherapy in chemotherapy-refractory HER-2 -positive and HER-2-negative advanced or metastatic breast cancer[J].Ann Oncol,2008,19:1068-1074.
  • 7Green MD,Francis PA,Gebski V,et al.Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer[J].Ann Oncol,2009,20:1813-1817.
  • 8von Minckwitz G,Jonat W,Fasching P,et al.A multicentre phase Ⅱ study on gefitinib in taxane-and anthracycline -pretreated metastatic breast cancer[J].Breast Cancer Res Treat,2005,89:165-172.
  • 9Dickler MN,Cobleigh MA,Miller KD,et al.Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer[J].Breast Cancer Res Treat,2009,115:115-121.
  • 10Dickler MN,Rugo HS,Eberle CA,et al.A phase Ⅱ trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer[J].Clin Cancer Res,2008,14:7878-7883.

共引文献154

同被引文献27

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部